Zealand Pharma A/S
Smedeland 26 B
Glostrup
DK-2600
Tel: 45-43-28-12-00
Fax: 45-43-28-12-12
Website: http://www.zp.dk/
Email: info@zp.dk
323 articles about Zealand Pharma A/S
-
Zealand Pharma Announces Financial Results for the Full Year 2023
2/27/2024
Zealand Pharma A/S announced the annual report for the year ended December 31, 2023, and provided a corporate update.
-
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
2/26/2024
Zealand Pharma A/S announced that Boehringer Ingelheim has reported that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase 2 trial [response difference: 64.8% (CI 51.1% - 78.6%), p-value (p<0.0001)].
-
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
2/20/2024
A Zealand Pharma A/S announced that it will host a conference call on February 27, 2024, at 2:00 pm CET following the announcement of financial results for the full year 2023.
-
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
1/19/2024
Zealand Pharma A/S today announces the receipt on 18 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from J O Hambro Capital Management.
-
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
1/10/2024
Zealand Pharma A/S announces the receipt on 9 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from Avoro Capital Advisors LLC.
-
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
1/2/2024
Zealand Pharma A/S announced that President and Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference at 10:10 a.m. ET on Thursday, January 4, 2024.
-
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
12/23/2023
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for Part 1 of the New Drug Application for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism for up to 3 weeks of dosing.
-
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
12/22/2023
Zealand Pharma A/S announced the submission of a New Drug Application to the US Food and Drug Administration for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome dependent on parenteral support.
-
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
12/4/2023
Zealand Pharma A/S, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines is hosting an Obesity R&D Event in London on Tuesday, December 5th to discuss the scientific rationale and clinical potential of the company’s differentiated product candidates.
-
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
11/30/2023
a Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.
-
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
11/9/2023
Strong progress across obesity pipeline, first PDUFA date for dasiglucagon in CHI in 2023 and solid financial position.
-
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
11/7/2023
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference.
-
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
11/3/2023
A Zealand Pharma A/S announced that it will host a conference call on November 9, 2023, at 2:00 pm CET following the announcement of results for the third quarter and first nine months of 2023.
-
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
10/17/2023
Zealand Pharma A/S announced presentations of clinical and non-clinical results for Zealand’s amylin analog ZP8396 at the Obesity Society Annual Meeting being held in Dallas, Texas from October 14-17, 2023.
-
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
10/5/2023
Boehringer Ingelheim and Zealand Pharma A/S announced the initiation of three Phase III trials investigating survodutide for people living with overweight or obesity.
-
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
9/8/2023
Zealand Pharma A/S announced that it will host an Obesity R&D Event in London on December 5, 2023 with management and external scientific experts in obesity.
-
Zealand Pharma to participate in upcoming healthcare conferences in September 2023
9/7/2023
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will participate in the following investor conferences in September:
-
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
8/30/2023
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism.
-
Zealand Pharma Announces Financial Results for the First Half of 2023
8/17/2023
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the interim report for the six months ended June 30, 2023 and provided a corporate update.
-
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
8/14/2023
a Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 17, 2023, at 2:00 pm CET following the announcement of results for the second quarter and first half of 2023.